Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Summary: For women facing advanced breast cancer who cannot tolerate harsh, intensive chemotherapy, finding an effective but gentle treatment is crucial. A recent study compared a standard chemotherapy cocktail known as "CMF" against a single oral drug called Capecitabine. The results were encouraging: women taking the oral Capecitabine pill lived, on average, four months longer than those on the standard CMF regimen (22 months versus 18 months). Additionally, while the standard treatment caused more severe issues like infections and low white blood cell counts, Capecitabine was generally better tolerated, with the main side effect being skin irritation on the hands and feet. Ultimately, this oral medication offers a life-extending option with fewer severe complications for vulnerable patients.